Health effects of long-term sleeplessness

-  To read Requis Pharma's First Patent application, Now ASSIGNED to the company, Please click on the URL below:

https://www.google.com/patents/WO2012170883A1?cl=en&dq=Wo+2012/170883&hl=en&sa=X&ei=pXyjUpu2I8TlsASqs4DICw&ved=0CDcQ6AEwAA

- For a copy of the latest patent application "Preparations for the Treatment of Sleep-Related Breathing Disorders" published in September 2014, see "NEW PATENT PUBLISHED" link on front page

Requisom for TREATMENT OF OBSTRUCTIVE SLEEP APNEA


A new prescription drug for the US and europe

This project is Requis Pharma's main initial focus


Sleep apnea is a highly prevalent condition affecting at least 4% of men and 2% of women.  It is defined by an increased apnea–hypopnea index of >5 with the associated symptom of daytime somnolence, and in the simplest terms can be classified as obstructive or central in nature. If untreated it is associated with increased cerebrovascular, CV and cancer morbidity/mortality. OSA is characterized by repetitive obstructions of the upper airway during sleep, despite increasing effort from respiratory pump muscles, resulting in cessation or reduction in airflow.

OSA leads to excessive daytime sleepiness, an increased risk of motor vehicle accidents, and is a risk factor for many serious symptoms including hypertension, cardiac arrhythmia, diabetes, and serious CV events such as myocardial infarction, stroke.  Sudden death is a feature of this ailment.


Requisom will target the US market as an improved, de-risked combination Rx product, involving the re-purposing of doxylamine. Given the estimates of undiagnosed OSA sufferers there may be over 20 million Americans who suffer from OSA.  The drug will be sold into a growing US sector for Rx sleep-aids currently worth >1,600 M p.a.  We see Requisom, once approved, reaching $2.4 Bn in sales in the US alone; and there is potential for effect in treatment of snoring, since anecdotal evidence for effect in that sleep-related breathing disorder has been observed. Requisom is likely to be a prescription drug in Europe.  Please contact the company's management (e-mail: l.knutsen@requispharma.com) for information on Requis' financial projections, including further information on the underlying assumptions utilized in estimating potential revenues..

To see Requis PhArma's second published patent application 

Please click on the URL below:

https://www.google.com/patents/WO2013074531A1?cl=en&dq=Wo+2013/074531&hl=en&sa=X&ei=BqujUv-PNJLesASEn4GYBw&ved=0CDkQ6AEwAA

Capturing new products based on the innovative science of L-tryptophan - an amino acid essential for human health

Cirrus, a new functional beverage for treatment of jet-lag and shift work disorder

Rapid market access and prospective revenue generation for requis Pharma 

Requis Pharma has devised Cirrus, a functional beverage for Jet-Lag Disorder (JLD) with a superb scientific basis: the company's second patent Wo 2013/074531 published 05/23/13.


A range of relaxation beverages are now marketed, such as: Dream Water, Drank, Relaxzen, i-Chill, Slow Cow, Koma Unwind but few of these actually target JLD, so a market opportunity exists.  Cirrus shares 2 of 3 ingredients with Requisom - specifically tryptophan and melatonin and represents an exciting new patented nutraceutical beverage. Melatonin adjusts circadian rhythm and tryptophan provides a path to relaxation, promoting positive mood as well as restorative sleep.

 

When marketed by a major company, Cirrus will initially target travelers that have passed through airport security – the company is devising a smartphone App. for handling JLD.  Requis is in dialogue with potential licensees, but also can execute plans for outsourced marketing of this new and ground-breaking product.